Human Herpesvirus 6 and 7 in Adults

Nearly every adult on the planet carries Human Herpesvirus 6 (HHV-6) and Human Herpesvirus 7 (HHV-7). Both viruses infect most children before age three, establish lifelong residency in the body, and then spend decades in a quiet standoff with the immune system. For the vast majority of adults, that standoff holds. But when it breaks down, whether from transplant-related immunosuppression, drug reactions, or still-mysterious triggers, these supposedly benign childhood infections can cause serious problems ranging from encephalitis to organ damage. The relationship between these two viruses and adult health turns out to be far more complex and medically relevant than their reputation as “roseola viruses” suggests.

Two Viruses, Not One

For years, HHV-6 was treated as a single virus. That changed in 2012, when the International Committee on Taxonomy of Viruses officially split it into two distinct species: HHV-6A and HHV-6B.¹ The reclassification was not just academic bookkeeping. The two viruses differ in which cells they prefer to infect, how they behave in the body, and which diseases they are linked to. HHV-6B is the one responsible for the common childhood rash illness roseola (also called sixth disease) and is the variant most frequently detected in transplant complications. HHV-6A is less well understood epidemiologically but has drawn attention for associations with neurological conditions and, as we will see, female infertility.

HHV-7, meanwhile, is a close cousin that also causes roseola-like illness in children, though it tends to infect slightly later than HHV-6B. It shares the same broad family (the betaherpesviruses, alongside cytomegalovirus) and the same basic strategy: infect early, hide for life. But HHV-7 has its own clinically relevant quirks, including the ability to reactivate HHV-6 from dormancy.

Where They Hide

Like all herpesviruses, HHV-6 and HHV-7 are never truly cleared from the body after initial infection. Both persist in salivary glands, which serve as a long-term reservoir. One study found HHV-6 DNA in about two-thirds of salivary gland biopsies from healthy people, and HHV-7 in three-quarters.² HHV-7 is shed in saliva much more frequently than HHV-6, which is thought to be the main route by which toddlers catch these viruses from the adults around them. Studies in transplant recipients have confirmed that the salivary glands remain a site of active, persistent infection for both viruses well into adulthood.³

HHV-6 also latently infects immune cells, particularly a subset of white blood cells. But it has a second, more unusual trick for long-term survival: it can stitch its entire genome into human chromosomes.

When the Virus Becomes Part of Your DNA

Both HHV-6A and HHV-6B have telomere-like sequences at the ends of their genomes that allow them to integrate directly into the telomeres of human chromosomes.⁴ When this integration happens in a sperm or egg cell, every cell in the resulting child will carry a full copy of the viral genome. This inherited form, called inherited chromosomally integrated HHV-6 (iciHHV-6), is present in roughly 0.4% to nearly 3% of the population, depending on the study and the geographic region examined.⁵ A large UK study found a prevalence of about 2.7%, with HHV-6B integration accounting for the overwhelming majority of cases and a notable north-south gradient across mainland Britain, with higher rates in Scotland than in England.⁶

For most people with iciHHV-6, the integrated virus sits quietly and causes no symptoms. But emerging evidence suggests it is not always completely inert. The same UK study found a nearly doubled risk of angina in people carrying iciHHV-6B, even after adjusting for known cardiovascular risk factors.⁶ Other research has flagged possible links to preeclampsia and reproductive disorders, though cause-and-effect remains unproven.⁵ The bigger practical headache is diagnostic: because people with iciHHV-6 have viral DNA in every nucleated cell, standard blood tests will show sky-high HHV-6 levels that look like a raging active infection. This can trigger unnecessary antiviral treatment, a pitfall that clinicians are still learning to avoid.

The Diagnostic Puzzle

Distinguishing active HHV-6 infection from latent virus or chromosomal integration is one of the trickiest problems in clinical virology. The most common diagnostic tools, PCR-based DNA detection and serology, each have blind spots. A positive PCR result in blood could mean active replication, low-level shedding from a latent reservoir, or iciHHV-6 where the viral DNA is simply part of the patient’s chromosomes.⁷ Serology is not much better, since virtually all adults have antibodies to HHV-6 from childhood infection, making it hard to tell old exposure from new activity.

When iciHHV-6 is suspected, clinicians can look for viral DNA loads that are disproportionately high relative to the clinical picture, or test non-blood tissues like hair follicles (which also carry the integrated genome). Confirming integration definitively requires specialized molecular techniques. The stakes of getting it wrong are real: a transplant patient falsely diagnosed with active HHV-6 infection may receive weeks of toxic antiviral drugs for a condition that was never actually present.

Reactivation After Transplant

The clinical setting where HHV-6 causes the most documented harm is after hematopoietic stem cell transplant (bone marrow transplant). When the immune system is profoundly suppressed during and after transplant, dormant HHV-6B frequently reactivates. The consequences can be severe. A study of allogeneic transplant recipients found that those with HHV-6 reactivation had roughly double the rate of death from causes other than cancer relapse compared to those without reactivation, at about 28% versus 14% at three years.⁸ In that same study, HHV-6 reactivation was independently linked to higher rates of graft-versus-host disease and to triggering cytomegalovirus reactivation on top of it.

A meta-analysis pooling data from eight studies confirmed the pattern, finding that patients with HHV-6B detection had significantly increased odds of non-relapse mortality.⁹ In critically ill hematology patients more broadly, HHV-6 was the most commonly detected herpesvirus in one large study, found in about 18% of patients, and its reactivation was independently associated with more than double the odds of hospital death.¹⁰ HHV-6 also plays a recognized role in post-transplant encephalitis, a rare but devastating complication, and in lower respiratory tract disease.¹¹

Treatment Options and Their Limits

There is no antiviral specifically designed for HHV-6. Clinicians borrow drugs developed for other herpesviruses, primarily foscarnet and ganciclovir. Both carry significant side effects: foscarnet can damage the kidneys and cause electrolyte disturbances, while ganciclovir suppresses bone marrow function, which is the last thing a transplant patient needs.

A prospective trial of foscarnet as preventive therapy in cord blood transplant recipients showed that the drug did suppress HHV-6 reactivation in the blood, cutting the rate of high-level virus detection from about 57% to about 18%. But it did not prevent HHV-6 encephalitis, which developed at similar rates in both groups.¹² That disconnect, suppressing virus in the bloodstream without protecting the brain, suggests the virus may reach the central nervous system by routes that systemic antiviral therapy does not adequately cover.

For HHV-6 encephalitis that has already developed, a retrospective analysis of over 120 cases found that combination therapy with both foscarnet and ganciclovir resulted in fewer long-term neurological complications than either drug alone. Roughly 38% of patients on the combination developed lasting problems or died, compared to about 56% on foscarnet alone and 64% on ganciclovir alone.¹³ Even the best available regimen, though, leaves a disturbingly high rate of poor outcomes. Better-targeted antivirals remain an unmet medical need.

HHV-7 Can Wake Up HHV-6

One of the more unusual findings in this field is that HHV-7 can directly trigger HHV-6B to reactivate from latency. In laboratory experiments, researchers found that cells carrying dormant HHV-6B could not be coaxed into producing active virus on their own, but when those same cells were infected with HHV-7, the latent HHV-6B roared back to life, eventually becoming the dominant virus while HHV-7 itself faded.¹⁴ This means the clinical effects attributed to HHV-6 reactivation may sometimes be set in motion by HHV-7 acting behind the scenes. It also complicates the picture for transplant physicians trying to figure out which virus is actually driving a patient’s symptoms.

Neurological Connections

Both viruses have been linked to neurological disease in adults, though through different levels of evidence. HHV-6B has drawn the most attention for a possible role in mesial temporal lobe epilepsy (MTLE), the most common form of drug-resistant epilepsy in adults. A study of surgically resected brain tissue found HHV-6B DNA in about 69% of patients with MTLE and in none of the control samples.¹⁵ The researchers went further, showing that HHV-6 infection of brain cells called astrocytes reduced levels of a glutamate transporter, a finding that could help explain the seizure activity. A separate study in a Chinese population found a lower but still elevated rate of HHV-6B in epilepsy tissue, about 28% versus 8% in controls, and noted a link between HHV-6B positivity and a childhood history of febrile convulsions.¹⁶

HHV-7 encephalitis in adults with healthy immune systems is rare but not unheard of. Case reports describe previously healthy adults developing seizures, confusion, and brain inflammation with HHV-7 DNA detected in their spinal fluid.¹⁷ One such case involved a 35-year-old man who developed limbic encephalitis with bilateral brain lesions and required aggressive treatment before recovering.¹⁸ These cases are individually anecdotal, but they establish that HHV-7 can cause central nervous system disease even without immunosuppression.

On a broader scale, both HHV-6A and HHV-6B have been studied as potential triggers for multiple sclerosis. In a nonhuman primate model, animals given HHV-6 through the nasal route showed no immediate symptoms but developed an MS-like neuroinflammatory disease significantly faster when it was later induced experimentally, compared to uninfected controls. The virus concentrated in brain lesions in a pattern resembling what has been found in human MS tissue.¹⁹ This does not prove HHV-6 causes MS in humans, but it offers a plausible mechanism by which the virus could accelerate neuroinflammation once the process has begun.

Drug Reactions and HHV-6 Reactivation

DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms) is a potentially life-threatening allergic reaction to medications, most commonly anticonvulsants and antibiotics. What makes DRESS unusual among drug reactions is that herpesvirus reactivation, particularly HHV-6, appears to be woven into the disease process itself. In a study of DRESS patients, HHV-6 reactivation was the most commonly detected, occurring in about 28% of those tested.²⁰ Patients with viral reactivation had roughly four times the odds of dying within a year, more than three times the odds of needing dialysis, and significantly more recurrent flares.

Case reports have documented HHV-6 in both the blood and biopsied liver tissue of DRESS patients with acute liver injury, pointing to the virus as a direct contributor to organ damage rather than a bystander.²¹ Whether the drug reaction triggers viral reactivation, or the reactivation worsens the drug reaction, or both happen in a self-reinforcing loop, is still debated. Either way, clinicians managing DRESS increasingly check for HHV-6 reactivation as part of their workup.

Chronic Fatigue Syndrome and Persistent Infection

The relationship between HHV-6, HHV-7, and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) has been studied for decades without fully resolving. The pattern that keeps appearing is that people with ME/CFS are more likely to have active (as opposed to merely latent) infections with these viruses. One study found active HHV-6, HHV-7, or parvovirus B19 infection in about 65% of ME/CFS patients compared to 13% of healthy controls, with higher levels of inflammatory markers in the patients who had active infections.²² Active infection was specifically associated with the hallmark symptoms of low-grade fever, swollen lymph nodes, and post-exertional malaise. A more recent study confirmed the same general pattern: active infection was present in about 45% of ME/CFS patients versus under 9% of healthy individuals, and those with active infection, especially co-infections with multiple viruses, had higher levels of both pro-inflammatory and anti-inflammatory cytokines.²³

The challenge here is the classic chicken-and-egg problem. Does persistent viral reactivation drive the immune dysfunction that characterizes ME/CFS, or does an already-dysfunctional immune system simply fail to keep these common viruses suppressed? Both explanations are plausible, and they are not mutually exclusive. What is clear is that these viruses are not mere passengers in a significant fraction of ME/CFS patients.

How These Viruses Dodge the Immune System

Part of what makes HHV-6 so successful at lifelong persistence is its sophisticated toolkit for manipulating the immune system. The virus encodes proteins that mimic human chemokine receptors, the signaling molecules that direct immune cells where to go. One well-studied HHV-6A protein, called U51A, can bind multiple human immune-signaling molecules and redirect immune cell traffic, potentially steering infected cells toward tissues like lymph nodes and lungs while simultaneously dampening the alarm signals that would normally attract virus-killing cells.²⁴ HHV-6 also alters the surface molecules on infected cells, making them less visible to the immune system, and can tweak the balance of inflammatory signals the body produces.²⁵ This immune manipulation does not just benefit HHV-6 itself; it can also create openings for other pathogens, including HIV, to spread more effectively.

A Possible Link to Female Infertility

One of the more surprising findings in recent years involves HHV-6A and unexplained female infertility. A study tested endometrial biopsies from women with primary unexplained infertility and found HHV-6A DNA in 43% of them, while detecting it in none of the fertile control women.²⁶ The infected women also showed changes in the types of immune cells present in the uterine lining and shifts in local cytokine levels that could theoretically interfere with embryo implantation. This was the first report of its kind and needs replication, but it opened a line of inquiry that had not previously been considered: that a virus nearly everyone carries might, in some women, silently infect the uterus and contribute to difficulty conceiving.

A Virus Older Than Human Migration

Chromosomal integration of HHV-6 is not a modern phenomenon. Evolutionary analyses have shown that the earliest integrations into the human germline occurred at least 50,000 to 100,000 years ago, before modern humans migrated out of Africa.²⁷ A study of ancient DNA recovered the first 11 historical HHV-6A and HHV-6B genomes, some dating to the 8th to 6th century BCE, and found that all known iciHHV-6A lineages were already present in historical European populations. The researchers concluded that HHV-6A likely stopped actively integrating into the germline within European-ancestry populations long ago, meaning the integrated copies found today are inherited relics of ancient events rather than new integrations.²⁸

This deep evolutionary history raises an interesting question: if carrying the virus in every cell were clearly harmful, natural selection would presumably have weeded it out over tens of thousands of years. That it persists at a prevalence of 1% to nearly 3% in some populations suggests either that the fitness cost is very small, that the integration occasionally confers some advantage, or that it simply integrates too frequently for selection to eliminate it. The honest answer is that nobody yet knows which of these explanations, or what combination, is correct.